The Hepatic Sinusoid in Chronic Liver Disease: The Optimal Milieu for Cancer
Albert Gibert‐Ramos(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Anabel Fernández‐Iglesias(Centro de Investigación Biomédica en Red), David Sanfeliu-Redondo(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Jordi Gracia‐Sancho(University Hospital of Bern), Peio Aristu-Zabalza(Departament de Salut), Sergi Guixé‐Muntet(Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas), Ana Martínez-Alcocer(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer)
Cited by 39
Related Papers
Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease
|Journal of Hepatology|2020|163
Global burden of disease attributable to metabolic risk factors in adolescents and young adults aged 15–39, 1990–2021
|Clinical Nutrition|2024|44
Oxidative Stress in Chronic Liver Disease and Portal Hypertension: Potential of DHA as Nutraceutical
|Nutrients|2020|26